Sector: Chemicals

Latest content

Applicants beware: patent oppositions are off the charts in India

Nearly 300% increase over a three-year span indicates greater attention being paid to publications in a jurisdiction where disputes are rising

09 November 2020

Meet the IV veteran creating an IP licensing business in the pharma space

Connie Wan of Seattle Gummy Company talks to IAM about the lessons she learned at the mega-NPE

06 November 2020

CEO’s patent comments illustrate high stakes of LG Chem IP campaign

The company plans to spin off its lucrative auto battery business, and executive says patents will be key to fending off competition from China

04 November 2020

Health insurer’s damages win against AstraZeneca creates new patent risks in The Netherlands

IP owners are liable to be sued by third parties if they assert rights that are subsequently invalidated, rules Dutch court.

27 October 2020

Chip tensions create IP opportunity in Asia for DuPont

Companies in China and South Korea link with chemicals giant in chip deals as policymakers seek to bulk up domestic supply chains

27 October 2020

French Court of Appeal SPC decision raises validity concerns

Merck IP right fails test in latest Article 3(a) judgment in case that may make France an even more attractive venue for nullity actions

26 October 2020

Companies from South Korea and Japan spearhead battery technologies patent rush

LG Chem and Toyota own two of the world’s largest portfolios in the field and as countries prioritise green energy this advantage may well translate into big money

23 October 2020

Korea’s push for chip independence could draw IP pushback

Worries about patent claims from Japanese rivals do not seem to have materialised yet, but trade secrets could be another concern

21 October 2020

Proposal to waive TRIPS is the latest sign of deepening global IP rifts over covid-19

WHO-backed proposal seeks to suspend key multilateral protections for patents and trade secrets

20 October 2020

Despite the praise, there may be less to Moderna’s covid patent pledge than meets the eye

The leading vaccine innovator has won plaudits for its commitment not to enforce its coronavirus-related IP rights against other mRNA inventors

15 October 2020

Unlock unlimited access to all IAM content